Correlation of Serum Levels of Vitronectin, Malondialdehyde and Hs- CRP With Disease Severity in Coronary Artery Disease

Alireza Yaghoubi, Morteza Ghojazadeh, Sakhavat Abolhasani, Hossein Alikhah, Fatemeh Khaki-Khatibi, Alireza Yaghoubi, Morteza Ghojazadeh, Sakhavat Abolhasani, Hossein Alikhah, Fatemeh Khaki-Khatibi

Abstract

Introduction: Vitronectin (VN), malondialdehyde (MDA) and high-sensitivity C-reactive rotein (hs-CRP) are cooperative agents involved in the atherosclerosis process. The study was conducted to assess the correlation of VN, MDA and hs-CRP with the severity of coronary artery disease (CAD).

Methods: Parameters such as serum VN, MDA and hs-CRP were measured in 250 subjects including 200 patients with angiographically diagnosed CAD (50 subjects with non-significant CAD, 50 with single vessel disease, 50 with double vessel disease, and 50 with triple vessel disease) and 50 CAD-free subjects as a control group. Serum VN was measured with ELISA; MDA was measured based on reaction with thiobarbituric acid (TBA); and hs-CRP level was measured by a Commercial Kit by Immunoturbidimetry.

Results: Serum VN, MDA and hs-CRP were significantly higher in patient groups compared to control group (P < .05). The mean value of MDA between 1 vessel and 3 vessel groups had significant difference (P = .01), also mean value of MDA between 2 vessel and control group and normal group showed significant difference (P < .001). The difference of MDA between 3 vessel and normal and 1 vessel and control group was significant (P < .001).

Conclusion: The association and correlation between VN, MDA and hs-CRP indicate their involvement in the atherosclerosis process that may lead to progression of CAD. Also, these findings suggested that serum levels of VN, MDA and hs-CRP can help as diagnostic and monitoring markers in CAD patients and as markers of disease severity.

Keywords: CAD; Correlation; Hs-CRP; MDA; Severity; Vitronectin.

References

    1. Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, Mockel M. et al. Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circulation. 2009;2(1):14–9. doi: 10.1161/CIRCINTERVENTIONS.108.795799.
    1. Thakur S, Gupta S, Parchwani H, Shah V, Yadav V. Hs-CRP-A potential marker for coronary heart disease. Indian J Fundam. 2011;1(3):2231–6345.
    1. Ekmekçi ÖB, Ekmekçi H. Vitronectin in atherosclerotic disease. Clinica Chimica Acta. 2006;368(1):77–83.
    1. Ekmekci H, Sonmez H, Ekmekci OB, Ozturk Z, Domanic N, Kokoqlu E. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis. 2002;14(3):221–5.
    1. Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999;31(5):539–44.
    1. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93(6):1825–30.
    1. Kannel WB. Overview of atherosclerosis. Clin Ther. 1998;20(B2-B17)
    1. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92.
    1. Köse K, Doğan P. Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes 2 Comparison of the antioxidant effect of Ginkgo biloba extract (EGb 761) with those of water-soluble and lipid-soluble antioxidants. J Int Med Res. 1995;23(1):9–18.
    1. Miyazaki T, Shimada K, Sato O, Kotani K, Kume A, Sumiyoshi K. et al. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis. 2005;179(1):139–45.
    1. Khaki-Khatibi F, Yaghoubi A, Rahbani N. Study of antioxidant enzymes, lipid peroxidation, lipid profile and immunologic factor in coronary artery disease in East Azarbijan. Inter J Med and Biomed Res. 2013;1(2):147–52.
    1. Ghodke SS, Padalkar RK, Bhagat SS, Ghone RA, Patil SM. hs-CRP: A “Golden Marker” of Inflammation and Coronary Artery Disease. IJHSR. 2012;2(6):42–46.
    1. Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813–8.
    1. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto Jr AM, Kastelein JJ. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195. doi: 10.1056/NEJMoa0807646.
    1. Patel VB, Robbins MA, Topol EJ. C-reactive protein: a’golden marker’for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68(6):521–4.
    1. Ou CY, Tseng YF, Lee CL, Chiou YH, Hsieh KS. Significant relationship between serum high-sensitivity C-reactive protein, high-density lipoprotein cholesterol levels and children with Kawasaki disease and coronary artery lesions. J Formos Med Assoc. 2009;108(9):719–24. doi: 10.1016/S0929-6646(09)60395-8.
    1. Coudray C, Charlon V, De Leiris J, Favier A. Effect of zinc deficiency on lipid peroxidation status and infarct size in rat hearts. Int J Cardiol. 1993;41(2):109–13.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
    1. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57(1):791–804.
    1. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91(3):3–6.
    1. Ekmekci H, Ekmekci OB, Sonmez H, Ozturk Z, Domanic N, Kokoqlu E. et al. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis. Clin Appl Thromb Hemost. 2005;11(1):63–70.
    1. Parker C, Stone O, White V, Bernshaw N. Vitronectin (S protein) is associated with platelets. Br J Haematol. 1989;71(2):245–52.
    1. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89(1):1–21.
    1. Testa R, Bonfigli A, Sirolla C, De Grazia G, Compagnucci P, Manfrini S. et al. Fibronectin and lipoprotein (a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications. Diabetes Nutr Metab. 2000;13(5):269–75.
    1. Asch E, Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin. 1990;85(5):1372.
    1. Mohri H, Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. J Clin Invest. 1990;96(5):605–9.
    1. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci. 1995;92(26):12426–30.
    1. Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C. et al. Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation. Cardiovasc Res. 2002;53(4):952–62.
    1. Cao DJ, Guo Y-L, Colman RW. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circulation Res. 2004;94(9):1227–34.
    1. Schleef R, Higgins D, Pillemer E, Levitt L. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989;83(5):1747.
    1. Wiman B, Hamsten A, editors editors. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Res Gate. 1990;16(3):207–16.
    1. Epstein FH, Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Enql J Med. 2000;342(24):1792–801.
    1. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(4):728–39.
    1. Stoop AA, Lupu F, Pannekoek H. Colocalization of Thrombin, PAI-1, and Vitronectin in the Atherosclerotic Vessel Wall A Potential Regulatory Mechanism of Thrombin Activity by PAI-1/Vitronectin Complexes. Thrombosis. 2000;20(4):1143–9.
    1. Pucheu S, Coudray C, Vanzetto G, Favier A, Machecourt J, Deleiris J. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. Free Radic Biol Med. 1995;19(6):873–81.
    1. Sharma SB, Garg S, Veerwal A, Dwivedi S. Hs-CRP and oxidative stress in young cad patients: a pilot study. Indian Journal of Clinical Biochemistry. 2008;23(4):334–6.
    1. Dincić D, Jović P, Obradović S, Popović P, Prcović M. Lipid peroxidation intensity and lipid status parameters in the estimation of the severity of ischemic heart disease. Voinosanit Preql. 1998;55(4):359–67.
    1. Wang Q, Qu L, Han C, Gu Z, Liu S. [Effect of chrysotile and cigarette smoking solution on DNA damage and repair in human alveolar epithelial cells] Zhonqhua Yu Fang. 2000;34(1):25–7.
    1. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C. et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. European Heart Journal. 2004;25(5):401–8.
    1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO. et al. Markers of inflammation and cardiovascular disease (application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association) Circulation. 2003;107(3):499–511.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren